The Dual NOD1/NOD2 Agonism of Muropeptides Containing a Meso-Diaminopimelic Acid Residue

Yulia A Dagil1, Nikolai P Arbatsky1, Biana I Alkhazova2

  • 1Laboratory of Clinical Immunology, National Research Center "Institute of Immunology of the Federal Medical-Biological Agency", Moscow, Russia.

Plos One
|August 12, 2016
PubMed

Insights

Muropeptides containing meso-diaminopimelic acid (meso-DAP) activate nucleotide-binding oligomerization domain (NOD) 1 and NOD2. This study reveals NOD2 recognizes non-terminal meso-DAP muropeptides, influencing innate immunity and vaccine adjuvant design.

Area of Science:

  • Immunology
  • Microbiology
  • Molecular Biology

Background:

  • Muropeptides, peptidoglycan fragments, activate innate immunity via NOD1 and NOD2.
  • Gram-negative bacteria muropeptides often feature non-terminal meso-diaminopimelic acid (meso-DAP), whose recognition is poorly understood.
  • Understanding muropeptide recognition is crucial for innate immunity research and therapeutic development.

Purpose of the Study:

  • To investigate the recognition of muropeptides with non-terminal meso-DAP by NOD1 and NOD2.
  • To elucidate the role of NOD1 and NOD2 in sensing Gram-negative bacterial muropeptides.
  • To refine the understanding of muropeptide-mediated immune activation.

Main Methods:

  • Developed a novel system using CRISPR/Cas9-mediated knockout (KO) of NOD1 and NOD2 genes in HEK293T cells.
  • Utilized NOD1/NOD2 knockout and overexpression systems.
  • Employed human monocytes and macrophages for cellular response assessments.

Main Results:

  • NOD2 recognizes various natural muropeptides with meso-DAP, preferably in non-terminal positions, at micromolar concentrations.
  • NOD2 accepts muropeptides with long/branched peptide chains and requires an intact N-acetylmuramyl residue.
  • Muropeptides with non-terminal meso-DAP can activate NOD1, potentially requiring peptidase pre-processing.

Conclusions:

  • Meso-DAP-containing muropeptides exhibit dual NOD1/NOD2 agonism, with cell-type-specific primary recognition (NOD2 in monocytes, NOD1 in macrophages).
  • Findings necessitate consideration of this dual recognition in evaluating cellular responses to muropeptides.
  • Results inform the design of muropeptide-based immunostimulants and vaccine adjuvants.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.5K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.4K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K